Freenome announced a merger with a SPAC that will provide roughly $330 million in gross proceeds, including a committed $240 million PIPE from institutional investors. The company plans to use the capital to commercialize its SimpleScreen multi-cancer blood test, currently under FDA review, and aims for potential 2026 product launches. CEO Aaron Elliott framed the deal as timed to an inflection point for blood-based cancer screening; investors named in coverage include Perceptive Advisors, RA Capital, Bain Capital Life Sciences and ADAR1 Capital. Media coverage noted Freenome’s position in a crowded liquid-biopsy market that includes incumbents such as Guardant Health. The transaction route — SPAC plus PIPE — reflects renewed public-market interest in diagnostics and screening plays, and Freenome’s regulatory path and reimbursement traction will determine commercial prospects.